{"pmid":32475056,"title":"Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment.","text":["Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment.","Dermatol Ther","Magnano, M","Balestri, R","Bardazzi, F","Mazzatenta, C","Girardelli, C R","Rech, G","32475056"],"journal":"Dermatol Ther","authors":["Magnano, M","Balestri, R","Bardazzi, F","Mazzatenta, C","Girardelli, C R","Rech, G"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32475056","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/dth.13706","keywords":["biologics, acute respiratory distress syndrome","covid-19","psoriasis","sars-cov-2"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668341932655378433,"score":9.490897,"similar":[{"pmid":32477419,"pmcid":"PMC7233295","title":"Psoriasis, biologic therapy, and the pandemic of the 21st century.","text":["Psoriasis, biologic therapy, and the pandemic of the 21st century.","The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a significant impact on lives all over the world. The complexity related to the new coronavirus and the clinical syndrome it causes is not yet fully understood. The impact of COVID-19 on patients with psoriasis under biologic agents is continuously being observed in this rapidly changing pandemic. A case-by-case evaluation must be made by dermatologists, and the final decision should be discussed and decided by both the patient and the specialist. Observations reveal that immunosuppressive therapy may have a role in the treatment of this virus, placing emphasis on the scenario of safety through maintenance of therapy with biologic agents, especially when there are no signs or symptoms related to the infection or contact with an infected patient.","Drugs Context","Nogueira, Miguel","Vender, Ron","Torres, Tiago","32477419"],"abstract":["The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a significant impact on lives all over the world. The complexity related to the new coronavirus and the clinical syndrome it causes is not yet fully understood. The impact of COVID-19 on patients with psoriasis under biologic agents is continuously being observed in this rapidly changing pandemic. A case-by-case evaluation must be made by dermatologists, and the final decision should be discussed and decided by both the patient and the specialist. Observations reveal that immunosuppressive therapy may have a role in the treatment of this virus, placing emphasis on the scenario of safety through maintenance of therapy with biologic agents, especially when there are no signs or symptoms related to the infection or contact with an infected patient."],"journal":"Drugs Context","authors":["Nogueira, Miguel","Vender, Ron","Torres, Tiago"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32477419","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.7573/dic.2020-4-10","keywords":["covid-19","sars-cov-2","biologic","coronavirus","psoriasis"],"weight":0,"_version_":1668437834916167680,"score":79.278366},{"pmid":32358864,"title":"Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits.","text":["Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits.","Dermatol Ther","Conforti, Claudio","Giuffrida, Roberta","Dianzani, Caterina","Di Meo, Nicola","Zalaudek, Iris","32358864"],"journal":"Dermatol Ther","authors":["Conforti, Claudio","Giuffrida, Roberta","Dianzani, Caterina","Di Meo, Nicola","Zalaudek, Iris"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358864","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/dth.13490","keywords":["covid-19","sars-cov-2","biologic treatment","biologics","psoriasis","psoriatic arthritis. guidelines"],"topics":["Prevention"],"weight":1,"_version_":1666138495316393986,"score":79.23522},{"pmid":32300516,"pmcid":"PMC7160052","title":"Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","text":["Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.","Dermatol Ther (Heidelb)","Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson","32300516"],"abstract":["With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here."],"journal":"Dermatol Ther (Heidelb)","authors":["Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300516","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s13555-020-00377-9","keywords":["biologics","covid-19","coronavirus","infection","pandemic","psoriasis","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666138494813077506,"score":77.98856},{"pmid":32468230,"pmcid":"PMC7255969","title":"Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","text":["Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis.","Dermatol Ther (Heidelb)","Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson","32468230"],"abstract":["The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis."],"journal":"Dermatol Ther (Heidelb)","authors":["Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468230","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s13555-020-00394-8","keywords":["biologics","covid-19","infection","pandemic","psoriasis","sars-cov-2","virus"],"topics":["Case Report"],"weight":1,"_version_":1668420887157669888,"score":74.46065},{"pmid":32343839,"title":"The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience.","text":["The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience.","The \"severe acute respiratory syndrome coronavirus 2\" (SARS-CoV-2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease-19 (COVID-19) and satisfying the epidemiological criteria for a pandemic [1]. As of April 1, 2020, more than one million COVID-19 positive cases have been identified and more than 54,000 deaths have occurred worldwide [2]. In Italy, 110,574 positive cases, 49,285 hospitalized patients and 13,155 deaths out of a population of 60,359,546 inhabitants, have been reported, respectively [3]. The highest number of deaths occurred in the northern Italian regions, i.e. Lombardy, Emilia-Romagna, Veneto and Piedmont [3].","Br J Dermatol","Gisondi, P","Facheris, P","Dapavo, P","Piaserico, S","Conti, A","Naldi, L","Cazzaniga, S","Malagoli, P","Costanzo, A","32343839"],"abstract":["The \"severe acute respiratory syndrome coronavirus 2\" (SARS-CoV-2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease-19 (COVID-19) and satisfying the epidemiological criteria for a pandemic [1]. As of April 1, 2020, more than one million COVID-19 positive cases have been identified and more than 54,000 deaths have occurred worldwide [2]. In Italy, 110,574 positive cases, 49,285 hospitalized patients and 13,155 deaths out of a population of 60,359,546 inhabitants, have been reported, respectively [3]. The highest number of deaths occurred in the northern Italian regions, i.e. Lombardy, Emilia-Romagna, Veneto and Piedmont [3]."],"journal":"Br J Dermatol","authors":["Gisondi, P","Facheris, P","Dapavo, P","Piaserico, S","Conti, A","Naldi, L","Cazzaniga, S","Malagoli, P","Costanzo, A"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343839","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/bjd.19158","keywords":["covid-19","biologics","interstitial pneumonia","psoriasis"],"locations":["Italy","Italian","Veneto","Piedmont"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666138495792447489,"score":69.51195}]}